RIGL Rigel Pharmaceuticals (RIGL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001034842
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
83
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $150.1K priced
What the filings say about RIGL
Insiders, 180 days
-$160.4K net sold
1 seller · 0% of sales under a 10b5-1 plan
Rigel Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, RIGEL PHARMACEUTICALS INC insiders sold a net $160.4K of stock across 22 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 26, 2026.
- The trade is 24.7% of the 10,125 shares held after it.
- No other insider sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ali-Jackson Kamil sold about $87.5K of RIGL on Jun 22, 2026; 83 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 19.8% of the 12,625 shares held after it.
- No other insider sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ali-Jackson Kamil sold about $72.9K of RIGL on May 26, 2026; 83 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 31.4% of the 12,722 shares held after it.
- No other insider sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MOOS WALTER H sold about $145.4K of RIGL on Feb 20, 2026, the largest insider sale at the company on our record; 83 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 4, 2025.
- The trade is 3.0% of the 57,235 shares held after it.
- 3 other insiders sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Financial Officer Schorno Dean L sold about $38.0K of RIGL on Feb 5, 2025; 3 other insiders sold within 30 days and 83 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 4, 2025.
- The trade is 3.5% of the 51,704 shares held after it.
- 3 other insiders sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Commercial Officer Santos David A sold about $39.4K of RIGL on Feb 5, 2025; 3 other insiders sold within 30 days and 83 funds added in the latest 13F quarter.22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$160.4K over 180 days
more than 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
83 funds bought in last quarter
more than 61% of Pharma & Biotech
Revenue
+64.1% year over year
more than 80% of Pharma & Biotech
Margin
124.7% net margin
more than 98% of Pharma & Biotech
Buybacks
$4.3M repurchased, FY to 2026-06-30
below 82% of Pharma & Biotech
Short interest
18.4% of the float short (float per yahoo 2026-10-27) · 12.8 days to cover · settled 2026-10-15
more than 85% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RIGL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+69.8%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RIGL: institutional holders (13F)
13F holdings, latest reported quarter
1,939,818 sh
$75.9M
1,843,504 sh
$72.1M
1,672,000 sh
$65.4M
1,039,994 sh
$40.7M
785,107 sh
$30.7M
Congress trades in RIGL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RIGL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Ali-Jackson Kamil
Filed 2026-06-22
$87.5K
RIGL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.5M position · as of 2026-07-31
1.5%
Inspire Fidelis Multi Factor ETF
$2.2M position · as of 2026-05-31
1.1%
First Trust Dow Jones Select MicroCap Index Fund
$2.4M position · as of 2026-06-30
0.9%
Nomura Healthcare Fund
$6.3M position · as of 2026-06-30
0.8%
iShares Genomics Immunology and Healthcare ETF
$1.4M position · as of 2026-07-31
0.7%
AUER GROWTH
$457.4K position · as of 2026-05-31
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
1 active
3
Phase 3
0 active
2
Phase 4
2 active
1
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Raul Rodriguez
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.7M
$8.7M
$1.8M
+22%
+20%
2024
$3.0M
$5.1M
$1.3M
-52%
-9%
2023
$3.4M
$2.1M
$1.1M
-59%
-8%
2022
$2.9M
$1.5M
$1.2M
-57%
-11%
2021
$3.4M
$866.9K
$1.3M
-24%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $160.4K sold by insiders over 180 days, 83 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RIGL financials
Revenue growth
+64.1%
XBRL, annual
Net margin
124.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$276.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RIGL
| FY Dec 2025 | $294.3M |
| FY Dec 2024 | $179.3M |
| FY Dec 2023 | $116.9M |
| FY Dec 2022 | $120.2M |
| FY Dec 2021 | $149.2M |
| Jun 2026 | $78.7M |
| Mar 2026 | $58.8M |
| Dec 2025 | $69.8M |
| Sep 2025 | $69.5M |
| Jun 2025 | $101.7M |
| Mar 2025 | $53.3M |
| Dec 2024 | $57.6M |
| Sep 2024 | $55.3M |
At each fiscal year end
Single quarter
Net margin, TTM
+116.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RIGL
| FY Dec 2025 | +124.7% |
| FY Dec 2024 | +9.8% |
| FY Dec 2023 | -21.5% |
| FY Dec 2022 | -48.7% |
| FY Dec 2021 | -12.0% |
| Jun 2026 | +22.0% |
| Mar 2026 | +14.7% |
| Dec 2025 | +384.0% |
| Sep 2025 | +40.2% |
| Jun 2025 | +58.6% |
| Mar 2025 | +21.5% |
| Dec 2024 | +24.9% |
| Sep 2024 | +22.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$78.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RIGL
| FY Dec 2025 | $75.2M |
| FY Dec 2024 | $31.0M |
| FY Dec 2023 | -$6.2M |
| FY Dec 2022 | -$74.2M |
| FY Dec 2021 | $5.3M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.11x
long-term debt only, 2026-03-31; equity 2026-06-30
Debt to equity RIGL
| FY Dec 2025 | 0.13x |
| FY Dec 2024 | 18.25x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.66x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.13x |
| Sep 2025 | 0.51x |
| Jun 2025 | 0.73x |
| Mar 2025 | 3.23x |
| Dec 2024 | 18.25x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.76x
TTM operating cash flow over long-term debt only, 2026-03-31
Cash flow to debt RIGL
| FY Dec 2025 | 1.44x |
| FY Dec 2024 | 0.52x |
| FY Dec 2023 | -0.10x |
| FY Dec 2022 | -1.84x |
| FY Dec 2021 | 0.29x |
| Jun 2026 | 1.76x |
| Mar 2026 | 1.76x |
| Dec 2025 | 1.44x |
| Sep 2025 | 1.14x |
| Jun 2025 | 1.10x |
| Mar 2025 | 0.59x |
| Dec 2024 | 0.52x |
| Sep 2024 | 0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+126.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RIGL
| FY Dec 2025 | +185.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -699.0% |
| FY Dec 2021 | -55.6% |
| Jun 2026 | +126.9% |
| Mar 2026 | +174.1% |
| Dec 2025 | +185.9% |
| Sep 2025 | +220.1% |
| Jun 2025 | +376.1% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+88.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RIGL
| FY Dec 2025 | +108.3% |
| FY Dec 2024 | +12.4% |
| FY Dec 2023 | -20.0% |
| FY Dec 2022 | -38.8% |
| FY Dec 2021 | -12.9% |
| Jun 2026 | +88.5% |
| Mar 2026 | +107.0% |
| Dec 2025 | +108.3% |
| Sep 2025 | +59.3% |
| Jun 2025 | +58.4% |
| Mar 2025 | +24.6% |
| Dec 2024 | +12.4% |
| Sep 2024 | +3.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -276%, not meaningful
Return on invested capital RIGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | +901.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +192.1% |
| Jun 2025 | +250.0% |
| Mar 2025 | +240.7% |
| Dec 2024 | +901.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+31.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RIGL
| FY Dec 2025 | +48.7% |
| FY Dec 2024 | +29.4% |
| FY Dec 2023 | -30.8% |
| FY Dec 2022 | -64.3% |
| FY Dec 2021 | -14.4% |
| Jun 2026 | +31.9% |
| Mar 2026 | +47.5% |
| Dec 2025 | +48.7% |
| Sep 2025 | +102.0% |
| Jun 2025 | +110.2% |
| Mar 2025 | +54.0% |
| Dec 2024 | +29.4% |
| Sep 2024 | +12.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
2.96x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing RIGL
| FY Dec 2025 | 2.20x |
| FY Dec 2024 | 17.16x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 2.32x |
| Mar 2026 | 1.40x |
| Dec 2025 | 2.20x |
| Sep 2025 | 4.58x |
| Jun 2025 | 3.46x |
| Mar 2025 | 8.65x |
| Dec 2024 | 17.16x |
| Sep 2024 | 73.55x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$916.5M
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term debt only, 2026-03-31, minus cash 2026-06-30
Enterprise value RIGL
| FY Dec 2025 | $789.3M |
| FY Dec 2024 | $299.5M |
| FY Dec 2023 | $2.6B |
| FY Dec 2022 | $2.6B |
| FY Dec 2021 | $4.5B |
| Jun 2026 | $708.0M |
| Mar 2026 | $520.1M |
| Dec 2025 | $789.3M |
| Sep 2025 | $519.6M |
| Jun 2025 | $341.3M |
| Mar 2025 | $335.6M |
| Dec 2024 | $299.5M |
| Sep 2024 | $293.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+8.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield RIGL
| FY Dec 2025 | +9.7% |
| FY Dec 2024 | +10.5% |
| FY Dec 2023 | -0.2% |
| FY Dec 2022 | -2.9% |
| FY Dec 2021 | +0.1% |
| Jun 2026 | +10.9% |
| Mar 2026 | +15.8% |
| Dec 2025 | +9.7% |
| Sep 2025 | +13.3% |
| Jun 2025 | +19.5% |
| Mar 2025 | +10.9% |
| Dec 2024 | +10.5% |
| Sep 2024 | +3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.01x
P/E over trailing EPS growth of 211%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing RIGL
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M |
| EPS (diluted) | 19.48 | 0.99 | -1.44 | -3.44 |
| Operating cash flow | $75.7M | $31.5M | -$5.7M | -$73.8M |
| Cash | $40.6M | $56.7M | $32.8M | $24.5M |
| Long-term debt | $52.5M | $60.0M | $60.0M | $40.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
RIGL Stock Sonar score 6/7 axes
Find similar shapesCompareRIGL ranks highest on profitability (97th percentile) and growth (80th), and lowest on insider conviction (25th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RIGL filings, in plain words
Are Rigel Pharmaceuticals insiders buying or selling RIGL?
In the 180 days to 2026-10-28, Rigel Pharmaceuticals insiders were net sellers, a net $160.4K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Rigel Pharmaceuticals insiders were net sellers of RIGL, a net $160.4K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
